Igenomix India Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 29-06-2024
- Paid Up Capital ₹ 2.31 Cr
as on 29-06-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 98.56%
(FY 2022)
- Profit 758.84%
(FY 2022)
- Ebitda 2715.76%
(FY 2022)
- Net Worth 28.88%
(FY 2022)
- Total Assets 21.77%
(FY 2022)
About Igenomix India
The Corporate was formerly known as Iviomics Research (India) Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.31 Cr, as per Ministry of Corporate Affairs (MCA) records.
Francisco Herrera, Deepak Khatter, and Ricardo Soriano serve as directors at the Company.
- CIN/LLPIN
U73200DL2012PTC302831
- Company No.
302831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 2012
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Igenomix India Private Limited offer?
Igenomix India Private Limited offers a wide range of products and services, including Medical Surgery & Treatment Centres, Medical Treatment Services.
Who are the key members and board of directors at Igenomix India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Francisco Herrera  | Additional Director | 30-Jun-2022 | Current |
Deepak Khatter  | Nominee Director | 20-Nov-2015 | Current |
| Ricardo Soriano | Additional Director | 30-Jun-2022 | Current |
Financial Performance of Igenomix India.
Igenomix India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 98.56% increase. The company also saw a substantial improvement in profitability, with a 758.84% increase in profit. The company's net worth Soared by an impressive increase of 28.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Igenomix India?
In 2021, Igenomix India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Igenomix India?
Igenomix India has a workforce of 25 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Igenomix India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Igenomix India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
